HLA-A and melanoma: Two PBMC samples isolated from peptide-vaccinated patients were tested and found to be capable of eliciting HLA-/MAA-specific degranulation against both HLA-A*0201-positive melanocytes and melanoma directly ex vivo (Figure 3).